GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, raised $22 million by offering 1.3 million units at $17, within the range of $16 to $18. The company offered 0.2 million more units than anticipated. Each unit consists...read more
GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to raise $18 million by offering 1.1 million units at a...read more
GBS, which is developing a saliva-based glucose monitoring system for diabetes in China, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $20 million by offering 1.2 million units at a price range of $16 to $18. Each...read more
Glucose Biosensor Systems (Greater China) Holdings, which is developing a saliva-based glucose monitoring system for diabetes in China, filed on Friday with the SEC to raise up to $23 million in an initial public offering. Glucose Biosensor Systems...read more
Saliva-based glucose device developer GBS prices IPO at $17 midpoint
GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, raised $22 million by offering 1.3 million units at $17, within the range of $16 to $18. The company offered 0.2 million more units than anticipated. Each unit consists...read more
Saliva-based glucose device developer GBS lowers deal size by 10% ahead of $18 million IPO
GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to raise $18 million by offering 1.1 million units at a...read more
Saliva-based glucose device developer GBS sets terms for $20 million IPO
GBS, which is developing a saliva-based glucose monitoring system for diabetes in China, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $20 million by offering 1.2 million units at a price range of $16 to $18. Each...read more
Spit take: Saliva-based glucose monitor Glucose Biosensor Systems re-files for a $23 million US IPO
Glucose Biosensor Systems (Greater China) Holdings, which is developing a saliva-based glucose monitoring system for diabetes in China, filed on Friday with the SEC to raise up to $23 million in an initial public offering. Glucose Biosensor Systems...read more